First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study
Journal of the National Comprehensive Cancer Network · 2025
DOI: 10.6004/jnccn.2024.7074 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Longbin Xiong und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen Universit…. Hauptthemen laut MEDLINE: Penile Neoplasms, Carcinoma, Squamous Cell, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The purpose of this study was to evaluate the efficacy and safety of PD-1 blockade combined with cisplatin and paclitaxel (TP)–based chemotherapy as first-line treatment for advanced penile squamous cell carcinoma (PSCC). Patients and Methods: A retrospective review was performed of 32 eligible patients with high-risk stage IV (cN3M0–1) PSCC who received first-line PD-1 blockade combined with TP-based chemotherapy at 5 medical centers (2019–2023). Clinical responses were assessed using RECIST version 1.1. Treatment-related adverse events (TrAEs) and postsurgical complications were graded according to CTCAE version 5.0. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Multiplex immunofluorescence was used to explore potential biomarkers and to present the tumor microenvironment landscape before and after treatment.
Results
After a median treatment duration of 4 cycles (range, 2–6), the overall objective response rate was 78.1% (25/32). Among 27 patients with locally advanced PSCC, 13 (48.1%) subsequently underwent consolidative surgery and 6 (22.2%) achieved a pathologic complete response (pCR). Additionally, 8 (25.0%) patients in the overall cohort underwent consolidated radiotherapy. Median follow-up was 21.1 months (95% CI, 14.1–42.7). Median PFS and OS were 15.0 months (95% CI, 11.4–not available [NA]) and 19.3 months (95% CI, 16.7–NA), respectively. All patients experienced TrAEs, with 50% (16/32) of them having grade ≥3 TrAEs. Higher intratumoral CD8+ T-cell infiltration was observed in pretreatment samples of responders compared with nonresponders ( P =.03). CD4+ T-cells, natural killer cells, and macrophages, among others, exhibited significant changes after treatment (all P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- State Key Laboratory of Oncology in Southern China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Urology, Cancer Hospital of Huanxing Chaoyang District Beijing, Beijing, China.
- Department of Radiology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- Department of Urology, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China.
Zitieren
APA
Xiong, L., Shan, X., Ma, H., Guo, S., Liu, J., Chen, X., Meng, W., Guo, B., Jiang, L., Yan, R., An, X., Shi, Y., Zhang, Y., Xue, T., Wei, L., Xu, D., Zhang, Z., Qin, Z., Yao, K., …, & Han, H. (2025). First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7074
Vancouver
Xiong L, Shan X, Ma H, Guo S, Liu J, Chen X, et al. First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2024.7074
BibTeX
@article{Xiong2025,
author = {Xiong, Longbin and Shan, Xingli and Ma, Huali and Guo, Shengjie and Liu, Jiyan and Chen, Xianda and Meng, Wenjun and Guo, Bin and Jiang, Lijuan and Yan, Ru and An, Xin and Shi, Yanxia and Zhang, Yijun and Xue, Ting and Wei, Lichao and Xu, Daming and Zhang, Zhiling and Qin, Zike and Yao, Kai and Li, Yajian and Spiess, Philippe E and Hu, Linjun and Xing, Nianzeng and Han, Hui},
title = {First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
doi = {10.6004/jnccn.2024.7074}
}
EUVIMED